medigraphic.com
Instituto Nacional de Salud Pública

2009, Number 4

<< Back Next >>

salud publica mex 2009; 51 (4)

Applicability of Framingham risk equations for studying a low-income Mexican population

Jiménez-Corona A, López-Ridaura R, Williams K, González-Villalpando ME, Simón J, González-Villalpando C

Language: English
References: 37
Page: 298-305
PDF size: 137.95 Kb.


ABSTRACT

Objective. To compare the predicted risk of coronary heart disease (CHD) and incident myocardial infarction (MI) using Framingham score equations with the observed rate of MI in Mexican subjects. Material and Methods. Longitudinal study that included 1 667 men and women aged 35 to 64 years without MI at baseline. Incident MI was defined by electrocardiogram or death certificate. The predicted risk of fatal MI, non-fatal MI, and both was calculated using Framingham score equations. Predicted to observed risk ratio of MI was estimated. Results. There were 34 incident MI cases and 24 MI deaths (median follow-up 6.2 years). The score equations overestimated the prediction of incident MI and CHD death (ratio 2.27, 95% CI, 1.19-3.34) and incident MI (ratio 2.36, 95% CI, 1.07-3.65) in men. Conclusions. The Framingham score overestimated incident MI and CHD death risk in men; however, other studies are needed to confirm our results for recalibrating the score for Mexican subjects.


REFERENCES

  1. Kirchhoff M, Davidsen M, Bronnum-Hansen H, Hansen B, Schnack H, Eriksen LS, et al. Incidence of myocardial infarction in the Danish MONICA population 1982-1991. Int J Epidemiol 1999;28(2):211-218.

  2. Jones DW, Chambless LE, Folsom AR, Heiss G, Hutchinson RG, Sharrett AR, et al. Risk factors for coronary heart disease in African-Americans: The Atherosclerosis Risk in Communities Study 1987-1997. Arch Intern Med 2002;162(22):2565-2571.

  3. Velazquez-Monroy O, Rosas-Peralta M, Lara-Esqueda A, Pastelin HG, Grupo ENSA 2000, Sánchez-Castillo C, et al. Prevalence and interrelations of non-communicable chronic diseases and cardiovascular risk factors in Mexico. Final outcomes from the National Health Survey 2000. Arch Cardiol Mex 2003;73:62-77.

  4. Perez G, Pena A, Sala J, Roset P, Masia R, Marrugat J. Acute myocardial infarction case fatality, incidence and mortality rates in a population registry in Gerona, Spain, 1990-1992. REGICOR Investigators. Int J Epidemiol 1998;27:599-604.

  5. Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998;24(13):861-867.

  6. Mitchell BD, Stern MP, Haffner SM, Hazuda HP, Patterson JK. Risk factors for cardiovascular mortality in Mexican-Americans and non-Hispanic whites: The San Antonio Heart Study. Am J Epidemiol 1990;131:423-433.

  7. Greenlee RT, Naleway AL, Vidaillet H. Incidence of myocardial infarction in a general population: The Marshfield Epidemiologic Study Area. WMJ 2002;101:46-52.

  8. Lowe LP, Greenland P, Ruth KJ, Dyer AR, Stamler R, Stamler J. Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch Intern Med 1998;158:2007-2014.

  9. Bobak M, Hense HW, Kark J, Kuch B, Vojtisek P, Sinnreich R, et al. An ecological study of determinants of coronary heart disease rates: A comparison of Czech, Bavarian and Israeli men. Int J Epidemiol 1999;28:437-444.

  10. National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment). Bethesda (MD): National Institutes of Health, 2002.

  11. Recommendations of the Second Joint Task Force of the European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998;19:1434-1503.

  12. British Cardiac Society, British Hyperlipidemia Society, British Hypertension Society, British Diabetic Association. Joint British recommendations prevention of coronary heart disease in clinical practice. Heart 1998;80(Suppl 2):S1-S29.

  13. Jackson R. Guidelines on preventing cardiovascular disease in clinical practice. BMJ 2000;320:659-660.

  14. Anderson HM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-362.

  15. Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factors categories. Circulation 1998;97:1837-1847.

  16. D´Agostino RB, Grundy S, Sullivan L, Wilson PWF. Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA 2001;286:180-187.

  17. Empana JP, Ducimetière P, Arvelier D, Ferrières J, Evans A, Ruidavets JB, et al. Are the Framingham and PROCAM coronary heart functions applicable to different European populations? Eur Heart J 2003;24(21):1903-1911.

  18. Thomsen TF, McGee D, Davidsen M, Jorgensen. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 2002;31:817-822.

  19. Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003;327:1267-1272.

  20. Liu J, Hong Y, D´Agostino RB, Wu Z, Wang W, Sun J, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study. JAMA 2004;291(21):2591-2599.

  21. Hense HW, Schulte H, Löwel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany ––results from the MONICA Augsburg and PROCAM cohorts. Eur Heart J 2003;24:937-945.

  22. Alvarez-Cosmea A, Diaz-Gonzalez L, Lopez-Fernandez V, Prieto-Diaz A, Suarez-Garcia S. Comparison of the SCORE and Framingham models in calculating high cardiovascular risk for a sample of males within the 45-65 age range in Asturias, Spain. Rev Esp Salud Publica 2005;79: 465-473.

  23. Stern MP, Gonzalez C, Mitchell BD, Villalpando E, Haffner SM, Hazuda HP. Genetic and environmental determinants of type II diabetes in Mexico City and San Antonio. Diabetes 1992;41:484-492.

  24. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: the fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-183.

  25. World Health Organization. Definition, diagnosis and classification of diabetes Mellitus and its complications: Report of a WHO consultation. Part 1: Diagnosis and classification of Diabetes Mellitus. Geneva: WHO, 1999.

  26. Prineas R, Crow R, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings. Littleton (MA): John Wrigth-PSG, 1982.

  27. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.

  28. Pan American Health Organization. Clasificación Estadística Internacional de Enfermedades y Problemas Relacionados con la Salud (CIE-10). Washington, DC: PAHO, 1995.

  29. Suka M, Sugimori H, Yoshida K. Application of the updated Framingham risk score to Japanese men. Hypertens Res 2001;24:685-689.

  30. Marrugat J, D´Agostino R, Sullivan L, Elosua R, Wilson P, Ordovas J, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health 2003;57:634-638.

  31. Wang Z, Hoy WE. Is the Framingham coronary heart disease absolute risk function applicable to aboriginal people? MJA 2005;182:66-69.

  32. Cappuccio FP, Oakeshott P, Strazzullo P, Kerry SM. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study. BMJ 2002;325:1271-1275.

  33. Brindle PM, McConnachie A, Upton MN, Hart CL, Smith GD, Watt GCM. The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract 2005;55:838-845.

  34. Folsom AR, Chambless LE, Duncan BB, Gilbert AC, Pankow JS. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care 2003;26:2777-2784.

  35. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE and DECODE risk equations do not provide reliable cardiovascular risk estimated in type 2 diabetes. Diabetes Care 2007;30:1292-1294.

  36. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomized controlled trials. BMJ 2001;323:75-81.

  37. Fischbacher CM, Bhopal R, Unwin N, White M, Alberti KGMM. The performance of the Rose questionnaire in South Asian and European origin populations: a comparative study in Newcastle, UK. Int J Epidemiol 2001;30:1009-1016.




2020     |     www.medigraphic.com